<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037088</url>
  </required_header>
  <id_info>
    <org_study_id>200614658</org_study_id>
    <secondary_id>C06-DA-119</secondary_id>
    <nct_id>NCT01037088</nct_id>
  </id_info>
  <brief_title>Effects of Vaporized Marijuana on Neuropathic Pain</brief_title>
  <official_title>CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Medicinal Cannabis Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Northern California Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study theorized that a low dose of vaporized cannabis could alleviate nerve injury
      pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Participants With 30% or Greater Reduction in Pain Intensity</measure>
    <time_frame>baseline to six hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Reflex Sympathetic Dystrophy</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Post-herpetic Neuralgia</condition>
  <condition>Spinal Cord Injury</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mild dose cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.53% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.29% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cannabis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo marijuana</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>3.53% THC by weight</description>
    <arm_group_label>Mild dose cannabis</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>1.29% THC by weight</description>
    <arm_group_label>Low dose cannabis</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>0.00% THC by weight</description>
    <arm_group_label>Placebo cannabis</arm_group_label>
    <other_name>placebo marijuana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 and less than 70

          -  Visual Analogue Scale (VAS pain intensity) greater than 3/10

          -  A negative urine drug screening test, i.e., no evidence of IV drug abuse

          -  Neuropathic pain due to reflex sympathetic dystrophy, peripheral neuropathy,
             post-herpetic neuralgia, post-stroke pain, multiple sclerosis or spinal cord injury

        Exclusion Criteria:

          -  Presence of another painful condition of greater severity than the neuropathic pain
             condition which is being studied.

          -  Subjects with moderate-severe major depression, bipolar/mania, bipolar II/hypomania
             and schizophrenia or schizoaffective disorder.

          -  Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl

          -  History of traumatic brain injury

          -  Uncontrolled medical condition, including coronary artery disease, hypertension,
             cerebrovascular disease, asthma, tuberculosis (TB), chronic obstructive pulmonary
             disease (COPD), opportunistic infection, malignancy requiring active treatment,
             active substance abuse (alcohol or injection drugs).

          -  Current use of marijuana (e.g., within 30 days of randomization)

          -  Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barth L Wilsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTSC Clinical Research Center, Sacramento VA Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cmcr.ucsd.edu/</url>
    <description>Center for Medicinal Cannabis Research website</description>
  </link>
  <reference>
    <citation>Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21. doi: 10.1016/j.jpain.2007.12.010. Epub 2008 Apr 10.</citation>
    <PMID>18403272</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2009</firstreceived_date>
  <firstreceived_results_date>December 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <keyword>neuropathy</keyword>
  <keyword>antinociception</keyword>
  <keyword>mood</keyword>
  <keyword>cognition</keyword>
  <keyword>neuropathic pain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place at the UCDMC and VA Northern California Pain clinics,UCDMC Spinal Cord Injury Clinic, and newspaper advertisements. Between December 2009 and March 2011, 59 patients were consented to enroll in the study.</recruitment_details>
      <pre_assignment_details>Twenty subjects did not receive study medication: 9 withdrew for various reasons and 11 were disqualified following a medical evaluation with subsequent disclosure of exclusionary criteria on a physical exam or laboratory finding.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants were randomized to a 3 way cross over design and received 3.53% THC, 1.29% THC and placebo cannabis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 3.53% THC</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1.29% THC</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who were randomized</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" spread="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With 30% or Greater Reduction in Pain Intensity</title>
        <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
        <time_frame>baseline to six hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>This was a cross over study. Ten of the 38 subjects who were exposed to placebo had a 30% reduction in pain intensity as compared to 21 of the 37 exposed to the low dose and 22 of the 36 receiving the medium dose of cannabis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Dose Cannabis</title>
            <description>3.53% THC by weight</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cannabis</title>
            <description>1.29% THC by weight</description>
          </group>
          <group group_id="O3">
            <title>Placebo Cannabis</title>
            <description>trace THC by weight</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With 30% or Greater Reduction in Pain Intensity</title>
            <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61" lower_limit="45" upper_limit="75"/>
                  <measurement group_id="O2" value="57" lower_limit="41" upper_limit="71"/>
                  <measurement group_id="O3" value="26" lower_limit="15" upper_limit="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mild Dose Cannabis</title>
          <description>3.53% 9-delta tetrahydrocannabinol by weight</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Cannabis</title>
          <description>1.29% 9-delta tetrahydrocannabinol by weight</description>
        </group>
        <group group_id="E3">
          <title>Placebo Cannabis</title>
          <description>0% 9-delta tetrahydrocannabinol by weight</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inclusion of patients with complex regional pain syndrome type I. In the past, there was no doubt that this disorder should be classified as classical neuropathic pain condition; Unmasking of blinding secondary to the psychoactive effects of cannabis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Barth Wilsey, MD</name_or_title>
      <organization>UCaliforniaDavis</organization>
      <phone>916-843-9082</phone>
      <email>blwilsey@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
